**Specifications Table**TableSubject areaBiologyMore specific subject areaArthritis and RheumatologyType of dataFiguresHow data was acquiredReal-time Polymerase Chain Reaction (Applied Biosystems PCR System 7500); Correlation analysisData formatAnalyzedExperimental factorsPeripheral blood mononuclear cells (PBMC) from RA, SLE, SS, DM or MCTD patients were freshly isolated. PBMC from early RA and established RA patients; PBMC from RA patients treated with tocilizumab were also collected. RNA was extracted from PBMC.Experimental featuresYY1 expression in autoimmune diseases or in RA patients treated with tocilizumab was detected by real-time PCR.Data source locationThe First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaData accessibilityData are presented in this article

**Value of the data**•These data can be compared to other scientific data addressing the role of YY1 in other disease.•These data provide insight into the function of YY1 in IL-6 production which can be of value for research groups from related fields.•These data allow other researchers to extend the role of YY1 in RA study.

1. Data {#s0005}
=======

Data describes YY1 expression in RA, SLE, SS, DM and MCTD patients. The data show YY1 is overexpressed in RA, but not in SLE, SS, DM or MCTD patients ([Fig. 1](#f0005){ref-type="fig"}). YY1 expression is also increased in early RA compared to healthy control ([Fig. 2](#f0010){ref-type="fig"}A), however, YY1 expression in asymptomatic subjects with RF or ACPA positive is not increased significantly ([Fig. 2](#f0010){ref-type="fig"}B). Furthermore, YY1 expression is positively correlated with serum CRP or ESR in RA ([Fig. 3](#f0015){ref-type="fig"}). However, in RA patients treated with anti-IL-6R monoclonal Ab tocilizumab, the YY1 expression after IL-6 blocking therapy is not increased significantly ([Fig. 4](#f0020){ref-type="fig"}).

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Patients {#s0015}
-------------

20 patients with systemic lupus erythematosus (SLE) fulfilled the 1997 revised American College of Rheumatology criteria [@bib2], 10 patients with Sjogren׳s syndrome (SS) fulfilled the American--European Group Criteria [@bib3], 10 patients with dermatomyositis (DM) fulfilled criteria described by Medsger [@bib4], 8 patients with mixed connective tissue disease (MCTD) fulfilled the classification criteria described by Alarcon-Segovia [@bib5] were enrolled for the study. Peripheral blood mononuclear cells (PBMC) from the patients was isolated by Ficoll. PBMC from early RA patients and asymptomatic subjects with RF or ACPA positive, PBMC from 6 RA patients before and after treated with tocilizumab (TCZ) for two months were also collected. All the PBMC collected was for detection of YY1 expression. Study protocols were approved by the Institutional Medical Ethics Review Board of the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

2.2. Real-time PCR analysis {#s0020}
---------------------------

Total RNA was extracted from PBMC cells, and real-time PCR was performed as previously described by us [@bib6], [@bib7]. The primers used in this study was as described by us [@bib1].

2.3. Statistical analysis {#s0025}
-------------------------

Differences between groups was analyzed by unpaired Student׳s *t*-test. Correlation analyses was done by Microsoft Excel. For all statistical analyses, *P* values less than 0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).
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![YY1 expression in PBMC from RA, SLE, SS, DM and MCTD patients. YY1 expression was over-expressed in RA compared to SLE, SS, DM and MCTD patients. HD: healthy donors; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SS: Sjogren׳s syndrome; DM: dermatomyositis; MCTD: mixed connective tissue disease. ^⁎^*P*\<0.05.](gr1){#f0005}

![Increased expression of YY1 in early RA, but not in asymptomatic subjects with RF or ACPA positive. **A,** YY1 expression in early RA and established RA. **B,** YY1 expression in asymptomatic subjects with RF or ACPA positive. HD: healthy donors. RF: rheumatoid factor; ACPA: anti-citrullinated protein antibodies. ^⁎^*P*\<0.05.](gr2){#f0010}

![Positive correlation between YY1 expression and CRP or ESR. **A,** Correlation analysis of YY1 expression and CRP. **B**, Correlation analysis of YY1 expression and ESR. CRP: C-reaction protein; ESR: erythrocyte sedimentation rate.](gr3){#f0015}

![YY1 expression in RA patients treated with tocilizumab. PBMC from RA patients 14, 28, 42 and 56 days' post tocilizumab treated was collected for detection of YY1 expression.](gr4){#f0020}
